In early-phase clinical trials, we observed a general decrease in tumor ADC following administration of PEGylated Recombinant Human Hyaluronidase PH20 (PEGPH20) as monotherapy. This decrease was related with reduction of tumor hyaluronan measured in biopsy samples. Reduction in ADC is suggestive of a decrease in tumor water content following hyaluronan depletion by PEGPH20.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords